 Shares of Kamada NASDAQ:KMDA moved lower by 2.5 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share fell 46.67 year over year to 0.08, which missed the estimate of 0.11.Revenue of 33,089,000 decreased by 6.14 from the same period last year, which missed the estimate of 36,370,000.Guidance Earnings guidance hasnt been issued by the company for now.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: Aug 12, 2020View more earnings on KMDATime: 08:30 AMET Webcast URL: Companys 52-week high was at 10.0052-week low: 4.40Price action over last quarter: Up 28.32Company Overview Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing and marketing of specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX etc. The company has Proprietary products and Distribution segments. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from Proprietary products segment and generates the majority of sales from the United States. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.See more from Benzinga Earnings Scheduled For August 12, 2020 Kamadas Earnings: A Preview Stocks That Hit 52-Week Highs On WednesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 